Pledpharma AB, of Stockholm, said the futility analysis in the study known as Pliant has been completed, and the data safety monitoring board found that the analysis turned up no negative impact on the anticancer effect of chemotherapy when the company's drug, Pledox (calmangafodipir), was used.